Pretreatment factors: association with prognosis (two-tailed P values)
| IL-2 alone | IL-2 + vaccine | |||||||
|---|---|---|---|---|---|---|---|---|
| Response | Survival* | Response | Survival* | |||||
| Sex | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Race | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Eastern Cooperative Oncology Group score (0 vs 1-2) | ≥0.1 | 0.03 | ≥0.1 | ≥0.1 | ||||
| Prior treatment | ||||||||
| Immunotherapy | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| IFN-α | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Radiotherapy | ≥0.1 | 0.04 | 0.01† | ≥0.1 | ||||
| Chemotherapy | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Hormonal therapy | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Baseline laboratory values | ||||||||
| WBC count | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Lymphocytes count | ≥0.1 | ≥0.1 | 0.05† | ≥0.1 | ||||
| Eosinophil count | 0.02† | ≥0.1 | 0.08 | ≥0.1 | ||||
| Platelet count | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Bilirubin | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| Creatinine | ≥0.1 | ≥0.1 | 0.04 | ≥0.1 | ||||
| TSH | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| FT4 | ≥0.1 | ≥0.1 | ≥0.1 | ≥0.1 | ||||
| No. metastatic sites | 0.02 | 0.06 | <0.0001 | <0.0001 | ||||